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Abstract
Objective: In a previous questionnaire study, more breast cancers were reported by women with intrahepatic
cholestasis of pregnancy (ICP) than by the controls. The aim of this study was to establish whether ICP is
associated with cancer in the Finnish Cancer Registry data, the study population being the same cohort as in the
questionnaire study.
Methods: The study population comprised 571 women with ICP in at least one pregnancy and 1,333 controls
from Tampere University Hospital in Finland during 1969–1988. The cancer data were obtained from the Finnish
Cancer Registry. The cancers were classified by ICD-O-3 and diagnosed during the period 1953−2013.
Results: In the ICP group, the odds ratio of cancers (OR 1.26, 95% CI 0.96–1.64), and breast cancer in particular
(OR 1.36, 95% CI 0.91–2.03), was slightly higher than in the control group. Seven percent of the ICP group and
5.3% of the control group had breast cancer.
Conclusion: Based on this study there is not a significant association between ICP and cancer. Earlier
observation in the questionnaire study regarding association between ICP and breast cancer cannot be confirmed
by this registry based study.
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Introduction
Intrahepatic cholestasis of pregnancy (ICP) is a reversible liver
disorder with pruritus as the main symptom, especially on the palms
and soles. An elevated serum bile acid and transaminase concentration
is also required for diagnosis [1]. In Europe, the incidence of ICP is
approximately 1%, but rates vary geographically [2]. In Finland, the
incidence is approximately 1.0−1.5% [3] and in Sweden the incidence
is 0.5−0.75% [4]. Hormonal factors seem to contribute to the
pathogenesis of ICP [5,6]. Estrogen may participate in the
development of cholestasis [7] and progesterone may impair hepatic
bile homeostasis [8]. Genetic factors are known to be involved in the
pathogenesis; ICP is inherited as a sex-limited dominant phenotype
and multiple genes are influential [9]. Multidrugresistant protein 3
(MDR3) is associated with up to 15% of ICP cases [10,11].
Environmental factors may also have a role in the pathogenesis of the
disorder [12]. In addition, a positive family history [13] and twin
pregnancies raise the risk of ICP [14].
Excessive exposure of endogenous estrogen over the lifetime may be
a causative factor of breast cancer [15]. Hormonal, genetic, and
environmental factors are known to have an impact on the aetiology
and pathogenesis of cancers and ICP. Cancer antigen 15-3 (CA15-3) is
a glycoprotein commonly found in breast cancer cells, and its levels in
serum reflect the amount of breast cancer cells in the body. CA15-3
levels are raised during pregnancy in general, but they are higher in
ICP pregnancies than in controls [16]. In an extensive registry-based
study, ICP was associated with an increased risk for later hepatobiliary
cancer. Hepatitis C infection was strongly associated with liver cancer,
but after adjusting for this diagnosis, women with ICP were still at
increased risk for liver malignancy. In addition, in a separate analysis
excluding all women with gallstone disease or cholangitis, women with
ICP had an increased risk for biliary tree malignancies [17].
A low number of child births has been associated with an increased
risk for breast cancer. Since mothers with ICP have been found to limit
their child number more often than controls [18], it may be speculated
whether this has increased the incidence of breast cancers. Primary
healthcare arranges almost exclusively maternity care in the Nordic
countries [19]. In Finland health centres maintain maternity health
clinics where a nurse or a midwife and a Family Doctor are responsible
for care [20]. The maternity health clinics in primary health care
usually detect ICP. If a pregnant woman complains of pruritus her
ALAT and bile acids values are screened. Either of these values being
elevated the mother is referred to an obstetrician [21]. If pruritus is
intolerable the mother is referred to the obstetric clinic without waiting
the results of the blood test.
A questionnaire study observed that ICP may be associated with an
elevated risk for breast cancer [22]. However, the study was based on
subjective information obtained from self-reports. The aim of the
present study was to investigate, using objective registry data, whether
ICP has an association with breast cancer or other cancers when using
the same cohort as the questionnaire study.
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Material and Methods
All ICP pregnancies at Tampere University Hospital (TUH) during
1969–1988 were collected from the patient records. From 1969 to 1986,
ICD-8 was used at TUH. Because ICD-8 did not include a precise code
for ICP, we checked all the obstetric codes that might contain ICP:
637.9 Toxicosis NUD, 639.00 Pruritus, 639.01 Icterus gravis, 639.09
Necrosis acuta et subacuta hepatis, and 639.98 Aliae definitae.
Thereafter, we checked the written diagnosis behind the code, and if it
referred to ICP, we included the case for further selection. ICD-9 was
used between 1987 and 1988, and it contained the appropriate codes
6467A Hepatosis gravidarum and 6467X Hepatopathia alia. The
diagnosis was verified from each patient record with the presence of
the main symptom of itching and abnormal laboratory test results. At
least one of the following was required: ASAT >35 U/l, ALAT >40 U/l,
or bile acids 6 μmol/l or more.
The study population comprised 687 ICP deliveries. The data
included some women with repeated ICP deliveries and each of these
women was studied as an individual case. The ICP group thus
contained 575 women. The proceeding and following subjects in the
maternity ward diary were taken as controls for each ICP case. There
were 1,374 controls in total. The groups were comparable regarding
age, educational level, and body mass index. The deliveries of mothers
with ICP took place at earlier gestational weeks than those of the
controls. Four women were ruled out from the ICP cases and 41 from
the controls because of a missing personal identity code. The final data
comprised 571 women with ICP and 1,333 controls.
The cancer data were obtained from the Finnish Cancer Registry in
January 2014 based on personal identity codes. All physicians,
hospitals, and other relevant institutions have had an obligation to
report every cancer to the Finnish Cancer Registry since 1961. The
database contains all the diagnosed cancers and cancer deaths in
Finland since 1961 and the most of cancers since 1953, when
systematic cancer registration was started [23]. The Finnish Cancer
Registry also contains information on all death certificates that
mention cancer. The Registry takes notice of the completeness and
accuracy of its data, and its completeness has been shown to be over
99% [24]. The Registry is upheld by the National Institute for Health
and Welfare of Finland. The study data included all reported cancers of
the cohort during 1953–1960, all registered cancers during 1961–2013,
and the location and behaviour of the cancer. The cancers were
reported by ICD-O-3 topographical codes [25]. Women who had had
more than one cancer were also included in the study. The cancers
were classified by ICD-O-3 codes into larger subgroups. Cancer
behaviour was classified as benign, unclear behaviour, carcinoma in
situ, or malignant.
The data were analysed using the SPSS System for Windows, Version
22.0. The results are presented as frequencies and percentages.
Statistical significance was tested with a chi-squared test. Binary
logistic regression analysis was performed to obtain odds ratios (OR)
and 95% confidence intervals (CI). The dependent variable was “ICP
or not”. T-test was performed to explore difference regarding age at the
diagnose moment of cancer. The cohort did not obtain informed
consent because the study is retrospective and does not have an effect
on treatment. The study has the approval of the Regional Ethics
Committee of Tampere University Hospital (R02149) and the National
Institute for Health and Welfare in Finland (THL/1051/5.05.00/2014).
Results
In the ICP group, 96 women (16.8%) had been diagnosed with at
least one cancer, compared to 185 women (13.9%) in the control group.
The difference was not statistically significant (p=0.098). Mothers with
ICP had a slightly higher risk for cancer (OR 1.26, 95% CI 0.96–1.64)
than the control mothers. None of the mothers with ICP and fifteen
(1.1%) of the controls had been diagnosed with two or more separate
cancers (p=0.011). One of the controls had had three separate cancers.
Three women had been diagnosed with a cancer before labour and all
of them were controls.
The occurrence of cancers is presented in Table 1. Breast cancer was
the most common cancer in both groups. The mothers with ICP had a
slightly higher risk for breast cancer (OR 1.36, 95% CI 0.91–2.03) than
the control mothers. Breast cancer was diagnosed at a slightly older age
in the ICP group than in the control group but the difference was not
statistically significant.
ICD-10
code
Cancer Mothers
with ICP
n=571
Control
mothers
n=1,333
Difference
n % n % %
units
p-
value
C50 Breast 40 7.0 70 5.3 1.7 0.133
C73-
C75
Thyroid and other
endocrine glands
6 1.1 5 0.4 0.7 0.075
C64-
C68
Urinary tract 4 0.7 3 0.2 0.5 0.116
C42 Haematopoietic and
reticuloendothelial
systems
2 0.4 2 0.2 0.2 0.382
C30-
C39
Respiratory and
intrathoracic organs
1 0.2 3 0.2 0.0 0.827
C40-
C41
Bone and articular
cartilage
1 0.2 3 0.2 0.0 0.827
C80 Unknown primary site 1 0.1 1 0.1 0.0 –
C00-
C14
Lip, oral cavity, and
pharynx
0 0.0 1 0.1 -0.1 0.513
C15-
C26
Digestive organs 7 1.2 19 1.4 -0.1 0.731
C45-
C49
Mesothelial and soft
tissue
0 0.0 1 0.1 -0.1 0.513
C43-
C44
Melanoma and other
malignant neoplasms of
skin
18 3.2 38 2.9 -0.1 0.721
C51-
C58
Female genital organs 14 2.5 35 2.6 -0.1 0.826
C69-
C72
Eye, brain, and other
parts of central nervous
system
3 0.5 8 0.6 -0.1 0.844
C77 Lymph nodes 2 0.4 7 0.5 -0.1 0.610
Table 1: The occurrence of cancers in mothers with ICP and the
controls.
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Melanoma and other malignant neoplasms of the skin as well as
cancers of the female genital organs were among the most common
cancers in both groups. Cancers of the thyroid and other endocrine
glands and urinary tract cancer were more common in the mothers
with ICP than in the controls, but the differences were not statistically
significant. Of the digestive organ cancers, hepatobiliary cancer was
also examined separately. Hepatobiliary cancer was found in one
mother with ICP and among none of controls. Most of the cancers
(nearly 90%) were malignant in both groups (Table 2). The difference
between the groups was not statistically significant (p=0.758).
Cancer behaviour Mothers with ICP (n=96) (%) Control mothers (n=185) (%)
Malignant 87.5 86.5
Carcinoma in situ 6.3 5.4
Unclear behaviour 0.0 1.1
Benign 6.3 7.0
Table 2: Cancer behaviour according to ICD-O-3 among mothers with ICP and the controls.
The mothers with ICP had been diagnosed with cancer at a slightly
older age, the mean age being 53.0 years in the ICP group and 51.8
years in the control group. The difference was 1.2 years (p=0.315). The
mean age of mothers who had not been diagnosed with cancer was
61.5 years among ICP mothers and 61.3 years among controls in
31/12/2013.
Discussion
The ICP group and the control group evinced minor differences in
most of the study outcome measures. The findings are in agreement
with former observations on the association of cancer and ICP. In the
control group, there were women who had been diagnosed with two or
more separate cancers, but in the ICP group each woman with cancer
had been diagnosed with only one cancer. ICP was associated with a
slightly higher risk for cancer, especially breast cancer.
The aim of the present study was to establish whether ICP is
associated with an increased risk for cancers, and especially for breast
cancer, which was the result found from the earlier study based on self-
reports. Despite the small loss of cases, the data were adequate. The
data obtained from the Finnish Cancer Registry can be considered
reliable.
Medications may have an impact on the risk for cancer. Over the
past decades, various treatments have been used for ICP. We have not
collected information about the medication for ICP among our study
population, and consequently the role of medication regarding the risk
for cancer cannot be evaluated.
A recent Swedish study did not find any clear association between
overall cancer and ICP [17], which is in agreement with our findings.
In the same study, an increased risk for later hepatobiliary cancer in
women with ICP was found (liver cancer: HR 3.61; and biliary tree
cancer: HR 2.62). In the aforementioned study, the occurrence of
hepatobiliary cancers was small in the ICP group (0.1–0.2%). Based on
the above study, the expectation value to find any hepatobiliary cancers
in our study was very small. However, one hepatobiliary cancer was
found in our ICP group, which exceeds the expectation value.
There is higher risk of hepatobiliary disease and particularly chronic
hepatitis among women with a history of ICP [26,27]. The latter
disease causes liver cirrhosis and is often complicated by hepatocellular
cancer[17]. Also cholelithiasis and chronic cholangitis are associated
with ICP [26,27] and are associated with gallbladder and
cholangiocellular cancer[17].
The Swedish registry study did not find any association between
breast cancer and ICP (HR 1.03). In our study, mothers with ICP had a
slightly higher risk for breast cancer than the control mothers (OR
1.36), although the difference was not statistically significant. The
occurrence of breast cancer was lower in the Swedish population
(1.6%) than in our Finnish population. Women’s risk for having breast
cancer before the age of 75 is 9.9% in Finland and 9.6% in Sweden [28].
Our longer follow-up time and the younger age of mothers in the
Swedish study might explain the difference. Nevertheless, the cohort
should be followed even longer because now the cohort represents
those who had been diagnosed with cancer at a fairly young age.
Premature delivery (gestation weeks <37) seems to increase the
mother’s risk for breast cancer later in life [29]. Formerly, it has been
found that ICP is associated with an elevated risk for delivery in
gestation weeks under 37 [14]. It can be considered that premature
delivery may increase the number of breast cancer cases among ICP
women.
A questionnaire study observed that the women with ICP reported
more breast cancer (6.3% vs. 3.7%, p=0.047) [22]. In our study, breast
cancer was found among 7.0% in the ICP group and among 5.3% in
the control group, the cohort being the same as in the questionnaire
study. In this registry study, however, the difference between the
groups is not statistically significant.
ICP has found to have a multifactorial genetic base. It may be
speculated that ICP is one expression of a larger group of genetic
diseases. Hormonal factors may be relevant in the pathogenesis of ICP
and breast cancer [5,6,15]. It may be speculated whether the same
hormonal factors have an effect on both diseases.
This is the first Finnish registry study on the potential association
between ICP and cancer. According to the writers’ knowledge there is
only one registry based study investigating the association between
ICP and cancer [17], and therefore the findings in this study may be
considered unique. However, former observations regarding the
association between ICP and breast cancer in the questionnaire study
could not be confirmed by this registry based study. A larger number
of ICP women and a longer follow-up time of the cohort might be
needed to confirm the results. Based on this study doctors do not have
to change their treating strategies and screen cancers because a woman
has a history of ICP.
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